MC2 Therapeutics-developed skin drug wins market share in Europe
Psoriasis cream Wynzora, which is marketed in Europe by Almirall, has generated EUR 7m in 2022.
by christian bundgaard, translated by daniel pedersen
MC2 Therapeutics and Almirall’s new psoriasis treatment, Wynzora, has been welcomed by several European countries in 2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
MC2 Therapeutics CEO steps down as board member
For subscribers
